Extensive research has demonstrated that VEGF inhibitors induce various adverse events, including but not limited to hypertension, proteinuria, hemorrhage and thrombosis, fistula formation, intestinal perforation, and posterior reversible encephalopathy syndrome (PRES) [2, 8]. The gene discussed is VEGFA; the disease is Posterior Leukoencephalopathy Syndrome.